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Abstract: Emerging infectious viruses have led to global advances in the development of specific
and sensitive detection techniques. Viruses have an inherent potential to easily mutate, presenting
major hurdles for diagnostics and requiring methods capable of detecting genetically diverse viral
strains. One such infectious agent is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
which emerged in December 2019 and has resulted in the global coronavirus disease 2019 (COVID-19)
pandemic. This study presents a real-time reverse transcription PCR (RT-PCR) detection assay for
SARS-CoV-2, taking into account its intrinsic polymorphic nature that arises due to genetic drift
and recombination, as well as the possibility of continuous and multiple introductions of genetically
nonidentical strains into the human population. This advance was achieved by using mismatch-
tolerant molecular beacons designed to specifically detect the SARS-CoV-2 S, E, M, and N genes.
These were applied to create a simple and reproducible real-time RT-PCR assay, which was validated
using external quality control panels (QCMD: CVOP20, WHO: SARS-CoV-2-EQAP-01) and clinical
samples. This assay was designed for high target detection accuracy and specificity and can also be
readily adapted for the detection of other emerging and rapidly mutating pathogens.
Keywords: COVID-19; SARS-CoV-2; molecular beacons
1. Introduction
Infectious diseases caused by pathogenic agents are among the most prominent lead-
ing causes of death worldwide. In the last few decades alone, humanity has experienced
the emergence and/or re-emergence of pathogens, which has led to epidemics and pan-
demics, such as those caused by human immunodeficiency virus (HIV), influenza, severe
acute respiratory syndrome (SARS), and Ebola. Evidently, viral pathogens are more often
than not the causative agents of emerging infections [1,2]. Currently, the world is facing
yet another pandemic, which was initially identified as an outbreak of pneumonia cases
of an unknown cause in December 2019 in Wuhan city, the capital of Hubei Province in
China. This respiratory disease was named coronavirus disease 2019 (COVID-19), after its
causative agent, which was revealed to be a novel coronavirus named SARS coronavirus
2 (SARS-CoV-2) [3]. SARS-CoV-2 is the third zoonotic human coronavirus that can cause
severe disease, with the other two being SARS-CoV and Middle East respiratory syndrome
coronavirus (MERS-CoV) [4–7].
As a member of the Coronaviridae family, SARS-CoV-2 has a positive-sense, single-
stranded ribonucleic acid (RNA) genome of ∼ 30,000 base pairs (bp), the largest genome
of all RNA viruses that infect humans. Through sequencing and phylogenetic studies,
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SARS-CoV-2 was classified in the genus Betacoronavirus along with SARS-CoV and MERS-
CoV [8]. It has been discovered that the SARS-CoV-2 genome has 14 open reading frames
(ORFs), with the first being ORF1ab, which encodes 15–16 nonstructural proteins (nsps)
and mainly comprises the replicase/transcriptase complex that is important for viral
replication [9]. Following ORF1ab, the four main structural proteins are encoded: spike
(S), envelope (E), membrane (M), and nucleocapsid (N). These proteins are constituents
of the coronavirus virion and have accessory functions in the life cycle of the virus [8,9].
The SARS-CoV-2 genome also encodes the accessory proteins 3ab, 6, 7ab, 8, 9bc, and
10, whose predicted functions are mostly based on sequence similarity with SARS-CoV
homologs [9,10]. Consequently, several aspects of the SARS-CoV-2 genome, proteome, and
clinical manifestations are still under investigation [11].
The information gained from studying previous coronaviruses has served as a basis
for SARS-CoV-2 research [12]. Similar to previous coronaviruses, SARS-CoV-2 mainly
causes respiratory illness outbreaks [7], and as such, patients infected with SARS-CoV-2
show symptoms of viral pneumonia, including coughing, breathing difficulties, fever
and, in the most severe cases, bilateral lung infiltration. However, a wide range of clin-
ical manifestations has been observed, and in some cases, patients exhibit neurological
symptoms [13,14].
Due to the severity of SARS-CoV-2 infection, it is imperative that molecular detection
assays be developed. These assays must be adaptable, specific, and sensitive, since this
virus is spreading rapidly, continuously receiving evolutionary pressures from the host’s
immune system, antiviral drugs, vaccines, and transmission/replication within human
populations of different genetic and environmental backgrounds [15–17]. SARS-CoV-2 has
acquired dozens of mutations and has been classified into a myriad of lineages [18–20],
highlighting the need to increase global efforts and improve detection strategies to account
for the variability of the virus. However, current diagnostic methods can be limited in
terms of sensitivity and specificity due to the polymorphic nature of SARS-CoV-2, and thus,
there is room for improvement [21–24].
Therefore, in light of the rapid spread and continuous evolution of SARS-CoV-2,
we developed a real-time reverse transcription polymerase chain reaction (real-time RT-
PCR) assay utilizing mismatch-tolerant molecular beacons, which can detect this novel
coronavirus [25]. The assay incorporates four beacons targeting the S, E, M, and N genes,
in addition to an internal positive control (IPC) and synthetic RNA transcripts of the
aforementioned gene targets that were used as positive controls. This assay was validated
using external quality assessments (EQAs) from the World Health Organization (WHO) and
Quality Control for Molecular Diagnostics (QCMD) and clinical samples on the premise of
SARS-CoV-2 diagnostic surveillance performed at the University of Cyprus.
2. Materials and Methods
2.1. Molecular Beacon and Primer Design
The molecular beacons, primers, and target amplicons used for this assay were cre-
ated de novo (Table 1). The assay was designed to detect small regions (95–147 nu-
cleotides) of the SARS-CoV-2 (GenBank accession number MN908947.3) S, N, M, and E
genes (Figure 1). Each oligonucleotide was designed using multiple sequence alignments
from SARS-CoV and SARS-CoV-2 sequences acquired through the GenBank database
(http://www.ncbi.nlm.nih.gov/GenBank, accessed on 26 February 2020): specifically, the
pathogenic strains SARS-Urbani (AY278741), SARS-Tor2 (AY274119), and SARS-CoV-2 and
the Italian SARS-CoV-2 isolate MT066156 (Figure 2). Sequence alignments were performed
using ClustalW [26] and Geneious® 11.1.4 [27] and were used to identify genomic regions
in the previously mentioned coronaviruses that were suitable for designing all oligonu-
cleotides pertinent to this assay. The molecular beacons and primers were aimed to detect
SARS-CoV-2 regardless of lineage.
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Table 1. Oligonucleotide PCR primers, target amplicons, and molecular beacons used in the real-time PCR assay.






22131 (F) S GGGAATTTGTGTTTAAGAATATTGATGG 22,131–22,158 MN908947.3
22277 (R) S GAAACCTAGTGATGTTAATACCTATTGGC 22,249–22,277 MN908947.3
26261 (F) E CGGAAGARACAGGTACGTTAATAG 26,261–26,284 MN908947.3
26355 (R) E AAGCGCAGTAAGGATGGCTA 26,336–26,355 MN908947.3
26672 (F) M GTTAATTTTCCTCTGGCTGTTATGG 26,672–26,696 MN908947.3
26788 (R) M CCTACAAGACAAGCCATTGC 26,769–26,788 MN908947.3
28531 (F) N CTACCGAAGAGCTACCAGAC 28,531–28,550 MN908947.3


















TIPC N/A GGGAATTTGTGTTTAAGAATATTGATGGTTAGCTGCTGTTTACAGTCCAAGATGGTAGTATTCTTGCTAGTTACACTAGCCATCCTTACTGCGCTT N/A 96 N/A
Molecular Beacons 5
MBgeneS S HEX-GGTGGGCCCTGAGGGAGATCACGCACTAAACCCACC-DABCYL 22,195–22,218 MN908947.3
MBgeneE E TET-CCTCCGCACGAAAGCAAGAAAAAGAAGTACGCCGGAGG-DABCYL 26,291–26,316 MN908947.3
MBgeneM M HEX-CCTCCGATCCAATTTATTCTGTAAACAGCAGCCGGAGG-DABCYL 26,724–26,749 MN908947.3
MBgeneN N HEX-CCTCCGTACCATCTTGGACTGAGATCTTTCATCGGAGG-DABCYL 28,574–28,599 MN908947.3
MBIPC N/A FAM-GCCCACGTACCATCTTGGACTGTAAACAGCAGCCGTGGGC-DABCYL N/A N/A
1 PCR primer, oligonucleotide, and molecular beacon names as they appear in the text; the orientation of the PCR primer is indicated in parentheses: F, forward; R, reverse. 2 Positions correspond to the
appropriate GenBank sequences; in the case of molecular beacons, the positions correspond to the target recognition sequences of the molecular beacon probe. 3 Amplicon length denotes the size in nucleotides
(nts) of the target amplicons for each of the four genes (S, E, M, N) as well as the internal positive control (IPC). 4 The specific SARS-CoV-2 genome that was employed as a reference to design the oligonucleotides
used in this assay can be found in GenBank (https://www.ncbi.nlm.nih.gov/genbank/, accessed on 26 February 2020) under accession number MN908947.3. 5 Underlined regions denote the stem of the
molecular beacons; FAM denotes 6-carboxy fluorescein; TET, N-TET-6-aminohexanol; HEX, N-HEX-6-aminohexanol; and DABCYL, N-[4-(4-dimethylamino)phenylazo]benzoic acid.
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The molecular beacons and primers targeting the E gene were designed to identify
all SARS-CoV and SARS-CoV-2 sequences used in the alignment, while the S, N, and M
genes were used for discriminatory testing specific for SARS-CoV-2. A synthetic IPC was
also designed using oligonucleotide sections of the aforementioned genes. The folding and
structure of each molecular beacon along with their thermodynamic details were examined
using the Mfold deoxyribonucleic acid (DNA) folding webtool [28]. Each molecular beacon
was designed so that the stems were six nucleotides long, were complimentary to each
other and had a high GC content. Furthermore, the molecular beacons of S, N, M, and E
were labeled with the quencher N-[4-(4-dimethylamino)phenylazo]benzoic acid (DABCYL)
at the 3′ end and N-HEX-6-aminohexanol (HEX) fluorophore at the 5′ end, except for the
E gene, which was labeled with N-TET-6-aminohexanol (TET), and the IPC, which was
labeled with 6-carboxy fluorescein (FAM). Imperative to the purposes of this assay was that
the loop section of each molecular beacon, which acts as a probe and is complementary to
the targeted gene fragment, was designed to be 24–26 nucleotides long, which constitutes
the beacons as mismatch tolerant. Whereas, in contrast to allele discrimination, these longer
loops are specific and form stable hybrids with their targets, yet their length allows them to
be tolerant toward mismatches from mutations that may occur in the genome of SARS-CoV-
2 due to recombination and genetic drift [29,30]. The molecular beacons were designed
with a high GC content to prevent them from being in an open conformation during PCR
in the absence of target. Analysis of the thermodynamic compatibilities of the primers and
molecular beacons along with primer self-dimer and heterodimer formation (primer-primer
and molecular beacon-primer) were analyzed using the Oligo Analyser tool (IDT, Integrated
DNA Technology, Coralville, IA, USA). Through this analysis, the primer-primer and
molecular beacon-primer thermodynamic compatibility was evaluated to ensure no cross
hybridization between primers and beacons of different genes, since the oligonucleotides
(molecular beacons and primers) were designed to have similar melting temperature
profiles. It is important to note that in contrast to the molecular beacons, the primers
were not designed to be mismatch tolerant, but they were specifically designed to detect
SARS-CoV-2. The molecular beacons were synthesized by Biosearch Technologies (Risskov,
Denmark), and the primers and other oligonucleotides were synthesized by Macrogen
Europe (Amsterdam, The Netherlands) and Biosearch Technologies (Risskov, Denmark).
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Figure 1. Assay design. Graphic illustration of the genome of SARS-related coronavirus 2 (SARS-CoV-2). (A) The genes of the
structural proteins targeted in the assay are indicated in the highlighted area. (B) The start and end locations of these genes as
well as the open reading frames are demonstrated by the nucleotide positions in the magnified area [31]. (C) The target genes are
further magnified to show the amplicons of each of the four genes (S, E, M, and N) integrated in the assay. The sequences of the
primers and molecular beacons are shown in bold, and the target sequences of amplicons are shown in boxes. Numbers that
represent the probe, forward, and reverse primers based on the SARS-CoV-2 reference genome (GenBank: MN908947.3) denote
the nucleotide positions of the start and end of the target amplicons. The gray spheres (left side of each beacon) indicate the
quencher N-[4-(4-dimethylamino)phenylazo]benzoic acid (DABCYL) at the 3′ end of the molecular beacon, while the orange
spheres (right side of each beacon) indicate the fluorophore N-HEX-6-aminohexanol (HEX) for the S, N, and M beacons at the 5′
end. The purple sphere indicates the fluorophore N-TET-6-aminohexanol (TET) for the E gene.
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Figure 2. Sequence alignments of the target genes S, E, M, and N. Sequences of gene regions that were used as target areas in the real-time RT-PCR assay to compare SARS-
CoV-2-specific genes from SARS-CoV-2 and hCoV-19/Italy strains to those of the pathogenic SARS-CoV strains SARS-Urbani and SARS-Tor2. The corresponding GenBank 
accession numbers are MN908947.3, MT066156, AY278741 and AY274119, respectively. Sequences in the S, M and N genes were targeted to distinguish SARS-CoV-2 from 
the rest of the viruses, while the E gene sequences were selected to identify SARS-CoV and SARS-CoV-2 strains. Numbers designate the position of nucleotides with respect 
to the SARS-CoV-2 genome (GenBank accession no. MN908947.3). The highlighted areas in the alignments show target sequences for the primers and molecular beacons, 
while areas that are not highlighted within targeted regions signify nucleotides that are not the same as those in the SARS-CoV-2 reference genome (GenBank accession 
no. MN908947.3). 
Figure 2. Sequence alignments of the target genes S, E, M, and N. Sequences of gene regions that were used as target areas in the real-time RT-PCR assay to compare SARS-CoV-2-specific
genes from SARS-CoV-2 and hCoV-19/Italy strains to those of the pathogenic SARS-CoV strains SARS-Urbani and SARS-Tor2. The corresponding GenBank accession numbers are
MN908947.3, MT066156, AY278741 and AY274119, respectively. Sequences in the S, M and N genes were targeted to distinguish SARS-CoV-2 from the rest of the viruses, while the E gene
sequences were selected to identify SARS-CoV and SARS-CoV-2 strains. Numbers designate the position of nucleotides with respect to the SARS-CoV-2 genome (GenBank accession no.
MN908947.3). The highlighted areas in the alignments show target sequences for the primers and molecular beacons, while areas that are not highlighted within targeted regions signify
nucleotides that are not the same as those in the SARS-CoV-2 reference genome (GenBank accession no. MN908947.3).
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2.2. Internal Positive Control
An internal positive control was developed, which was a synthetic oligonucleotide
designed as a mosaic of fragments of the S, E, M, and N genes (Table 1). The IPC amplicon
was designed so that it could be amplified by the forward primer for the S gene and the
reverse primer for the E gene, while the molecular beacon target sequence was comprised
of fragments of the M and N genes. The IPC was compared against the National Center for
Biotechnology Information (NCBI) database [32] to ensure that the design was unique and
did not recognize other sections of the SARS-CoV-2 genome or the human genome. The
IPC was used as a reaction control and it was added during the real time RT-PCR stage.
2.3. Thermal Profiles of Molecular Beacons
Melting curve analysis was performed on a 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) to assess the thermodynamic characteristics
of the molecular beacons. To establish the optimal fluorescence, a variety of molecular
beacon concentrations were tested. Ultimately, each reaction volume was 25 µL and
consisted of 1.5 µL of MgCl2 (50 mM), 2 µL of molecular beacon, 1 µL of a single-stranded
oligonucleotide complementary to the target sequence (100 pmol/µL), and 20.5 µL of dH2O.
To note, the different concentrations that were tested for the molecular beacons were 5, 7.5,
and 10 pmol/µL, for a total of 10, 15, and 20 pmol per reaction. The PCR cycling conditions
consisted of 1 cycle for 2 min at 95 ◦C, followed by 50 cycles split in two steps. The first
step, during which data were collected, was at 80 ◦C for 30 s, decreasing by 1 ◦C per cycle,
and the second step was at 80 ◦C for 10 s, decreasing by 1 ◦C per cycle. Fluorescence was
measured at 535 nm for HEX, 521 nm for TET, and 495 nm for FAM, and the fluorescence
was recorded at each cycle. Following the completion of the run, the fluorescence signal
data were normalized and plotted.
2.4. RNA Transcripts
Synthetic RNA transcripts of each gene target amplicon were developed. These
RNA transcripts were transcribed from DNA templates by in vitro transcription using a
MEGAscript T7 transcription kit (Ambion, Houston, TX, USA) in accordance with the
manufacturer’s specifications. Specifically, to make the RNA transcripts of each gene target,
DNA templates were amplified using PCR and forward primers (Table 1) that encompassed
the T7 RNA polymerase promoter recognition site (TAATACGACTCACTATAGG) at the
5′ end. For the S, E, M, and N genes, DNA templates were generated using SARS-CoV-
2 RNA (BetaCoV/Germany/BavPat1/2020 p.1” grown in cell culture (Charité, Berlin,
European Virus Archive goes Global, EVAg)); thus, RT-PCR was performed to generate
these templates. However, for the IPC, a single-stranded DNA template was used for the
generation of the T7-IPC DNA template.
The volume of each PCR to generate DNA templates was 50 µL, which contained
25.0 µL of 2× Platinum SuperFi RT-PCR Master Mix from the SuperScript IV One-Step
RT-PCR System (Thermo Fisher Scientific, Waltham, MA, USA), 12.5 µL of nuclease-free
water, 1 µL of 20 pmol/µL each primer, 0.5 µL of SuperScript IV RT Mix (Thermo Fisher
Scientific, Waltham, MA, USA) and 10 µL of 103 copies per µL SARS-CoV-2 RNA. Prior to
amplification, the RNA was incubated at 70 ◦C for 20 s and then placed on ice for 1 min.
The conditions for the amplification were as follows: 1 cycle for 10 min at 50 ◦C; 1 cycle for
2 min at 98 ◦C; 40 cycles of 98 ◦C for 10 s, 53–56 ◦C (S: 55 ◦C, E: 56 ◦C, M: 53 ◦C, N: 54 ◦C)
for 10 s and 72 ◦C for 30 s; and 1 cycle of 72 ◦C for 5 min. For the IPC RNA transcript,
each reaction contained 25 µL of Platinum™ Hot Start PCR 2X Master Mix (Thermo Fisher
Scientific, Waltham, MA, USA), 18 µL of nuclease-free water, 1 µL of 20 pmol/µL each
primer, and 5 µL of single-stranded IPC DNA template at 104 copies per µL, for a total
reaction volume of 50 µL. The conditions of amplification were as follows: 1 cycle at 94 ◦C
for 2 min; 40 cycles at 94 ◦C for 30 s, 56 ◦C for 30 s and 72 ◦C for 30 s; and 1 cycle at 72 ◦C
for 5 min.
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The RNA transcripts were purified using NucAway™ Spin Columns Mix (Thermo
Fisher Scientific, Waltham, MA, USA). The eluates were then quantified using a NanoDrop®
ND-1000 (NanoDrop Technologies, Wilmington, DE, USA). To ensure that there were no
traces of DNA template in the RNA transcripts, real-time PCR was performed. Then, real-
time RT-PCR was performed to check that the RNA transcripts were properly amplified
(as indicated below).
2.5. Real-Time RT-PCR: Uniplex and Duplex Reactions
The assay was designed to be used in uniplex and in duplex when each target is run
with the IPC. The samples were analyzed by real-time RT-PCR performed on a 7900HT
Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using TaqPath™
1-Step Multiplex Master Mix (No ROX) (Life Technologies, Frederick, MD, USA). Each
30 µL reaction consisted of 10.0 µL of RNA, 7.5 µL of 4X TaqPath™ 1-Step Multiplex Master
Mix, 1.5 µL of 20 pmol/µL each primer, 3.0 µL of 5 pmol/µL molecular beacon, and 6.5 µL
of dH2O. The primers and molecular beacons for all genes are shown in Table 1. The
reverse transcription cycling conditions consisted of 1 cycle at 25 ◦C for 2 min, followed by
1 cycle at 53 ◦C for 10 min and 1 cycle at 95 ◦C for 2 min. This was followed by 5 cycles at
95 ◦C for 3 s and 53 ◦C for 30 s. Finally, there were 35 cycles at 95 ◦C for 3 s and 53 ◦C for
30 s, when data collection took place. In these runs, no-template controls (NTCs) (dH2O)
were also added as negative controls, while synthetic RNA transcripts (103 and 106 copies
per µL) and SARS-CoV-2 RNA (103 copies per µL) (BetaCoV/Germany/BavPat1/2020
p.1” grown in cell culture (Charité, Berlin, EVAg)) were used as positive controls. The
controls were assayed in duplicate for each reaction. Following the completion of the run,
the fluorescence signal data were normalized and plotted.
For duplex real-time RT-PCR, the protocol was adapted to account for the increased
number of primers and molecular beacons. This protocol was specifically performed for
the S, M, and N genes, and each of the genes was amplified with the IPC in the same
reaction. The final volume of the reaction was increased to 40 µL, and each contained the
following: 10 µL of SARS-CoV-2 RNA at 106 copies/µL (BetaCoV/Germany/BavPat1/2020
p.1” grown in cell culture (Charité, Berlin, EVAg)) or RNA transcripts, 10 µL of IPC target
at 106 copies/µL, 7.5 µL of 4× TaqPath™ 1-Step Multiplex Master Mix, 3 µL of the two
molecular beacons (5 pmol/µL) in each reaction, 1.5 µL of each primer at 20 pmol/µL,
and 0.5 µL of dH2O. Notably, for the S-IPC duplex reaction, a new forward primer was
designed for the S-gene target, (F) 22,157 (GGTTATTTTAAAATATATTCTAAGCACACGC,
22,157–22,187). For validation of the duplex reactions, a NTC (dH2O) was added as a
negative control. The targets were also run in uniplex reactions to compare the fluorescence
signal between the uniplex and duplex. The cycling conditions remained the same as those
in the uniplex real-time RT-PCR. The fluorophores FAM for IPC and HEX for S, M, and N
were selected specifically because their excitation wavelengths have little-to-no overlap in
their emission spectra. Following the completion of the run, the fluorescence signal data
were normalized and plotted.
2.6. Validation and Clinical Samples
Validation was accomplished by testing the assay on two external quality assessment
(EQA) programs. The first EQA program for the detection of SARS-CoV-2 was hosted
by the WHO (WHO SARS-CoV-2 EQAP (2020)). This program provided a panel of five
samples of dried, extracted coronavirus RNA (including SARS-CoV-2 RNA in different
dilutions and RNA from other currently circulating human coronavirus RNA) as well
as a positive control SARS-CoV-2 RNA sample. The second program was from QCMD
(QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study), which provided a
total of eight samples in transport medium. These programs were designed to evaluate a
laboratory’s ability to detect SARS-CoV-2 (COVID-19) using routine molecular methods,
and the results were reported during June 2020.
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The assay was further validated under the premise of diagnostic surveillance testing
that was performed for students and personnel of the University of Cyprus from September
2020–January 2021 as part of the university’s SARS-CoV-2 surveillance. Nasopharyngeal
samples were collected using nasopharyngeal swabs (Biocomma, Shenzhen, China), were
placed in tubes with preservation medium (Biocomma, Shenzhen, China), and stored
in the fridge (4 ◦C) for a maximum of 4 h before RNA was extracted. RNA extraction
was performed using a QIAmp Viral RNA Mini Kit (Qiagen, Hilden, Germany) and a
QIAcube Connect machine (Qiagen, Hilden, Germany) in accordance with the manufac-
turer’s specifications. Notably, samples were collected using the pooling method, with
an average of five samples per pool, and study subjects from positive pools were tested
again using new individual samples. Bioethical approval was received by the Cyprus
National Bioethics Committee (EEBK EΠ 2020.01.192), and to ensure patient anonymity, all
samples were double coded; thus, connections could not be made between the samples
and the corresponding study subjects. The collection, processing, and use of samples was
in compliance with the rules and regulations of the Cyprus National Bioethics Committee.
3. Results
3.1. Molecular Beacon Thermal Denaturation Profiles
For each molecular beacon, the fluorescence for the beacon-target hybrids and for
the beacon without target was plotted against temperature to ascertain their thermal
characteristics, as well as to identify the appropriate melting temperature for the molecular
beacons to hybridize with their targets (Figure 3). As shown in Figure 3, in the absence of
the target, the molecular beacons alone displayed a melting temperature of approximately
60 ◦C, while the largest difference in fluorescence signal between molecular beacons
alone and beacon-target hybrids occurred from 35–55 ◦C. Taking into account the higher
fluorescence signal of beacon-target hybrids vs that of beacon alone and the melting
temperatures of the primers used in this assay (Table 1), a temperature of 53 ◦C was
selected for the real-time RT-PCRs. Additionally, the optimal concentration that was
established for the molecular beacons was 15 pmol per reaction.
3.2. Real-Time RT-PCR Validation and Testing
The assay was first tested using SARS-CoV-2 RNA (BetaCoV/Germany/BavPat1/2020
p.1” grown in cell culture (Charité, Berlin, Germany, EVAg)) (Figure 4, Table 2). As shown
in Figure 4, all target regions were successfully amplified, and the molecular beacons were
able to bind to their targets and properly fluoresce, while in the absence of the target (black
dots), there was no amplification or fluorescence signal, as expected. Furthermore, for all
genes and the IPC, the signal exceeded the threshold at approximately the 32nd–35th cycle.
In Figure 5, the duplex reactions of each of the S, M, and N genes in combination with the
IPC can be observed. All targets were successfully amplified, and the molecular beacons
fluoresced, indicating that there was no cross hybridization and that the duplex reactions
did not hinder the results. In the absence of the target, there was no amplification and no
fluorescence signal (black dots). The IPC exceeded the threshold at the 19th–20th cycle,
while the S, M, and N beacons exceeded the threshold at the 20th–23rd cycle.




Figure 3. Thermal denaturation profiles of the molecular beacons for S, E, M, and N and the artificial 
internal positive control (IPC). Melting curve analysis was used to determine the thermal denatur-
ation profiles of the molecular beacons (described in the Materials and methods). The figure demon-
strates normalized fluorescence thermal transitions of molecular beacons, found at the bottom part 
Figure 3. Thermal denaturation profiles of the molecular beacons for S, E, M, and N and the artificial
internal positive control (IPC). Melting curve analysis was used to determine the thermal denaturation
profiles of the molecular beacons (described in the Materials and methods). The figure de onstrates
normalized fluorescence thermal tr nsitions of molecular beacons, found at the bottom part of the
plot shown in orange, and beacon-target complexes, found at the top part of the plot shown in purple.
The y-axis represents the normalized fluorescence data, while the x-axis represents the temperature.
Life 2021, 11, 1146 11 of 17
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cence, while the x-axis represents the thermal cycles. The intermittent red line represents the thresh-
old cycle. 
Figure 4. Uniplex real-time RT-PCR of SARS-CoV-2 genes (S, E, M, and N genes) and the artificial
IPC. On the left side f fi , a representation of the quencher and flu rophores carried by
each molecular beacon is shown. The gray spheres indica e the quencher DABCYL at the 3′ end of
the molecular beacon, while the orange spheres indicate the fluorophore HEX for the S, N, and M
beacons at the 5′ end. The purple sphere indicates the fluorophore TET for the E gene. The green
sphere indicates the fluorophore 6-carboxy fluorescein (6-FAM) for the IPC. On the right side of each
molecular beacon schematic, the fluorescence signal graph is shown for the molecular beacons and
their respective targets. The negative control is indicated with black dots. The y-axis represents
fluorescence, while the x-axis represents the thermal cycles. The intermittent red line represents the
threshold cycle.
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Table 2. Real-time RT-PCR results of human SARS-CoV-2 specimens.
Sample ID of Specimen Analyzed RT-PCR Result
4
S E M N
EVAg 1
1 Purified RNA of SARS-CoV-2 cell culture supernatant + + + +
WHO 2
2 2020-01 (SARS-CoV-2) + + + +
3 2020-02 (SARS-CoV-2) + + + +
4 2020-03 (NEGATIVE) − − − −
5 2020-04 (OC43) − − − −
6 2020-05 (SARS-CoV-2) + + + +
7 Positive control (SARS-CoV-2) + + + +
QCMD 3
8 CVOP20S2-01 (SARS-CoV-2) + + + +
9 CVOP20S2-02 (NL63) − − − −
10 CVOP20S2-03 (SARS-CoV-2) + + + +
11 CVOP20S2-04 (OC43) − − − −
12 CVOP20S2-05 (NEGATIVE) − − − −
13 CVOP20S2-06 (SARS-CoV-2) + + + +
14 CVOP20S2-07 (SARS-CoV-2) + + + +
15 CVOP20S2-08 (SARS-CoV-2) + + + +
1 EVAg, European Virus Archive goes Global. 2 WHO, World Health Organization, External Quality Assessment Program for the Detection
of SARS-CoV-2 by RT-PCR (2020) (WHO SARS-CoV-2 EQAP (2020)). Program code SARS-CoV-2-EQAP-01. 3 QCMD, Quality Control for
Molecular Diagnostics, QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study. Program code CVOP20. 4 Detectable real-time
PCR amplification signal is denoted by the symbol (+), which indicates consistent CT values ≤ 45 for each of the four SARS-CoV genes
assayed in this experiment, including an internal positive control (IPC). An undetectable signal (CT values > 45) is denoted by (−) and
indicates the absence of template cDNA.
Following testing on purified SARS-CoV-2 RNA, two EQAs were used for the vali-
dation of the assay, one from the WHO (WHO SARS-CoV-2 EQAP (2020)) and one from
QCMD (QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study) (Table 2). For
the WHO EQA, the assay successfully identified all blinded samples as well as the positive
control. This assay displayed the sensitivity needed to identify the SARS-CoV-2 RNA
samples included in the WHO EQA at low, medium, and high concentrations (7.11 × 104,
7.42 × 105 and 1.14 × 106 copies/mL), while it indicated sufficient specificity since it
did not identify the negative control and the human coronavirus (hCoV) OC43 RNA. For
the QCMD EQA, the assay successfully identified all blinded samples, with SARS-CoV-2
concentrations ranging as low as ~2 × 102 copies/mL and as high as ~2 × 105 copies/mL.
Similar to the WHO panel, the assay showed no amplification signal and did not identify as
positive hCoV NL63, hCoV OC43 or the negative control in the QCMD EQA panel. Based
on the results, the 15 samples included in Table 2, the purified SARS-CoV-2 RNA, and the
samples of the two EQA panels, the assay is sensitive enough to detect SARS-CoV-2 in sam-
ples containing varying concentrations and specific enough to discriminate SARS-CoV-2
from other human coronaviruses, displaying 100% detection ability and 100% specificity.
For the SARS-CoV-2 surveillance testing performed for students and personnel at
the University of Cyprus from September 2020–January 2021, 534 pooled samples were
collected, with an average of 5 samples per pool, for a total of 2231 study subjects tested
using this assay. From this testing we had identified 22 positive pools and the study subjects
from pools that were identified as positive were called in for resampling, and 15 were
identified as positive through individual testing using this assay, and an additional one
was identified as positive through rapid testing. Importantly, not all targets were required
to be performed at once, samples were routinely tested by one target and SARS-CoV-2
positivity was confirmed by a second target, provided the negative and positive controls
were correct. The positive controls were in concentrations of 103 copies per µL and 106
copies per µL, were utilized in every run, and the average threshold cycle was 31.7 ± 1.7,
and 21.6 ± 1.1 respectively.




Figure 5. Duplex real-time RT-PCR of SARS-CoV-2 genes (S, M, and N genes) and the artificial IPC. On the left side, a 
schematic representation of the quencher and fluorophores carried by each molecular beacon (S, M, and N) with the IPC 
is shown. The gray spheres indicate the quencher DABCYL at the 3′ end of the molecular beacon, while the orange spheres 
indicate the fluorophore HEX for the S, N and M beacons at the 5′ end. The green sphere indicates the fluorophore 6-FAM 
for the IPC. On the right side of each schematic of the molecular beacons (S, M, and N) with the IPC, the fluorescence 
signal graph is shown for the molecular beacons and their respective targets. The negative control is indicated with black 
Figure 5. Duplex real-time RT-PCR of SARS-CoV-2 genes (S, , a ifi ial I . n the left side, a
schematic representation of the quencher and fluorophores carried by each molecular beacon (S, M, and N) with the IPC is
shown. The gray spheres indicate the quencher DABCYL at the 3′ end of the molecular beacon, while the orange spheres
indicate the fluorophore HEX for the S, N and M beacons at the 5′ end. The green sphere indicates the fluorophore 6-FAM
for the IPC. On the right side of each schematic of the molecular beacons (S, M, and N) with the IPC, the fluorescence signal
graph is shown for the molecular beacons and their respective targets. The negative control is indicated with black dots.
The y-axis represents fluorescence, while the x-axis represents the thermal cycles. The intermittent red line represents the
threshold cycle.
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4. Discussion
The past SARS-CoV epidemic left the future possibility of re-emergence or emergence
of other coronaviruses as highly probable [25]. This fact stimulated vigilance toward these
viruses and provided us with the basis to develop diagnostic tests faster for other viruses,
such as the current SARS-CoV-2 pandemic. The molecular beacon-based real-time RT-
PCR assay presented here was originally developed for SARS-CoV by our laboratory [25]
(US Patent No. 7,709,188 B2, issued 4 May 2010) and was designed with the capability
for adaptation for such viruses and polymorphisms that may arise during the course
of their epidemics/pandemics. This rapid and accurate assay, which was modified and
further developed for SARS-CoV-2 detection, is an essential tool for the assessment and
optimization of disease prevention measures established to safeguard the population, and
it can be modified for other infectious agents that harbor a capacity for mutations and
constitute a threat to public health.
The sequence identity between SARS-CoV and SARS-CoV-2 has been reported to be
79.5%, and despite this high degree of similarity, there are distinct differences between
their genomes, some of which relate to their transmissibility and clinical outcomes [33].
The bioinformatic analysis performed for this study, specifically the multiple sequence
alignment, elucidated regions of higher and lower similarity within the structural genes S,
E, M, and N between SARS-CoV (Urbani and Tor2) and SARS-CoV-2 (MN908947.3 and
MT066156) used for this study (Figure 2). Thus, the region in the E gene that was selected
as a target serves as a screening part of the assay because it is conserved among these
SARS viruses, and even within SARS-CoV-2, 98.8% of the E protein of SARS-CoV-2 strains
worldwide is highly conserved [34]. Similarly, the M protein has also been reported to have
a slower rate of evolution and is also highly conserved [35,36]; however, along with the
S and N proteins, which tend to evolve faster [36], regions with higher variability were
selected for this assay to discriminate between SARS viruses (Figure 2). It is important
to note that numerous mutations have already been reported. Taking the S gene as an
example, there are at least 8 mutations/deletions in all variants of concern [37], which
serve as evidence of the current existing variability that can very well impact current
testing methods and show the potential for the accumulation of additional mutations in
the near future.
It is therefore important for testing methods to account for the variability in SARS-
CoV-2, which arises despite its nsp 14 proofreading capabilities [38]. Nonetheless, SARS-
CoV-2 receives evolutionary pressures, and as such, numerous lineages are generated that
encompass different sets of mutations and deletions [39]. Reports have already shown that
these mutations and deletions compromise SARS-CoV-2 detection assays [21–24], thereby
highlighting the urgent need for the development of screening assays specifically designed
to accommodate the polymorphic nature of the virus. A strength of the assay presented
in this study has addressed this issue through mismatch-tolerant (“sloppy”) molecular
beacon technology [29], which allows for the detection of polymorphisms that may occur
in the target sequence. Importantly, the specificity of the beacons is not compromised
by a small number mismatched base pairs since the beacon-target duplex is long enough
to account for these unexpected polymorphisms [30]. Furthermore, the sensitivity and
specificity of the assay is increased since four target regions were selected on four different
genes, thereby maximizing the probability of detecting SARS-CoV-2 and minimizing the
likelihood of false positive and false negative results. The latter is further supported by
both the IPC designed for this assay and the RNA transcript positive controls of each gene.
The present assay exhibited 100% specificity and sensitivity when tested with EQA sam-
ples from the WHO and QCMD. It was able to distinguish and identify SARS-CoV-2 from
other human coronaviruses, even at borderline concentrations as low as ~2× 102 copies/mL.
However, to improve upon the limitations of this assay, and in order for it to move to
clinical or commercial settings, it would require it to be compared with other already
available methods [40], as well as a larger cohort to enable more detailed measurements
of the limit of detection and precision of the assay. Furthermore, it is important to keep
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in mind that the pooling method that was utilized for the validation of the assay with the
public diagnostic surveillance at the University of Cyprus would be applicable for low
prevalence settings.
Nonetheless, during the testing of this assay at the University of Cyprus for public
diagnostic surveillance testing, 16 individual samples were identified as corresponding
to SARS-CoV-2 infection out of the 534 pooled nasopharyngeal samples, which were later
sequenced as part of a publication regarding a molecular epidemiological study of SARS-
CoV-2 infection in Cyprus [41]. In this separate publication, the majority of these 16 samples
were classified within the B.1.258 lineage, while the lineages B.1.177 and B.1.1.29 were
also identified [41]. Yet, even though certain mutations/deletions, as mentioned above,
have been reported to compromise SARS-CoV-2 real-time PCR testing methods, such
as ∆H69/V70 [21], which was also found in the B.1.258 lineage, the present assay was
unaffected since it did not target those mutated regions of the genome. Nevertheless,
the assay was limited by the SARS-CoV-2 lineages that were circulating [41] during the
period of the public diagnostic surveillance, and as such, the assay was not applied to
a more diverse set of lineages. Moreover, as the pandemic progresses and SARS-CoV-2
is evolving, the assay must be tested with samples from new variants, such as the Delta
variant of concern, which was not available during the development and validation of
the assay (EQAs June 2020 and public diagnostic surveillance samples September 2020–
January 2021). Hence, vigilance must be exercised, and we are regularly checking publicly
available genomes from the GISAID database (https://www.gisaid.org/, accessed on
4 October 2021) [42], to ascertain that the number of accumulated mutations does not
impact the primers (which are not mismatch tolerant), and is not exceeding the tolerance
capabilities of the molecular beacons, ensuring that they can still bind to their targeted
regions and consequently detect SARS-CoV-2. Nonetheless, another benefit of the design
of this assay is that it provides the advantage of being easily and rapidly adaptable if the
above scenario occurs.
Overall, we present an accurate and reliable uniplex real-time RT-PCR assay, which
can also incorporate an IPC. This assay is based on molecular beacons specifically designed
to allow for mutations that may arise from the evolutionary pressures that SARS-CoV-2
experiences. This study lays down the foundational work and presents the methodology
relevant for this assay to be extrapolated for commercialization and clinical testing at a
later stage. This assay offers a fast and efficient way to diagnose SARS-CoV-2 and can
serve as a valuable and easily adaptable detection method for current and future mutating
infectious agents.
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